Comparative Pharmacology
Head-to-head clinical analysis: LORAZ versus TEMAZEPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORAZ versus TEMAZEPAM.
LORAZ vs TEMAZEPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to gamma-aminobutyric acid (GABA) type A receptors at the benzodiazepine binding site, potentiating the effect of GABA, leading to increased chloride ion influx, neuronal hyperpolarization, and inhibition of neurotransmission.
Positive allosteric modulator of GABA-A receptors, enhancing the effect of GABA by increasing chloride ion influx, leading to neuronal hyperpolarization and sedation.
2-6 mg orally or intravenously daily in divided doses; usual range 2-10 mg/day
10-20 mg orally at bedtime, up to 30 mg in severe insomnia.
None Documented
None Documented
Terminal elimination half-life: 12–15 hours in healthy adults. Extended in elderly (15–20 hours), hepatic impairment (up to 50 hours), and obesity.
Clinical Note
moderateClorazepic acid + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Clorazepic acid is combined with Fluticasone propionate."
Clinical Note
moderateLorazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Lorazepam is combined with Fluticasone propionate."
Clinical Note
moderateTemazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Temazepam is combined with Fluticasone propionate."
Clinical Note
moderateTerminal elimination half-life is 8–20 hours in healthy adults (mean ~15 hours); may be prolonged in elderly (up to 50 hours) and in hepatic impairment (up to 40 hours); clinical context: typical dosing interval is 12–24 hours.
Renal: ~85% as glucuronide conjugates and ~10% as unchanged drug. Biliary/fecal: ~5%.
Renal excretion of conjugated metabolites (primarily as glucuronide) accounts for approximately 80% of an oral dose; fecal excretion accounts for about 12%; less than 1% is excreted unchanged in urine.
Category C
Category D/X
Benzodiazepine
Benzodiazepine
Temazepam + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Temazepam."